Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (DE:0ET)
STUTTGART:0ET
Esperion (0ET) Stock Price & Analysis
1 Followers
0ET Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.67 - €2.99
Previous Close€1.66
Volume100.00
Average Volume (3M)772.00
Market Cap
€324.45M
Enterprise Value€496.10M
Total Cash (Recent Filing)$82.25M
Total Debt (Recent Filing)$266.17M
Price to Earnings (P/E)N/A
Beta1.45
Next Earnings
May 07, 2024EPS Estimate
€0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume772
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.26
Enterprise Value/Gross Profit4.26
Enterprise Value/Ebitda-3.33
Forecast
1Y Price Target
€6.90Price Target Upside263.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Esperion News
Bulls Say, Bears Say
Bulls Say
Financial OutlookProfitability could be achieved with a sustainable financial outlook beyond that, not solely reliant on milestone payments.
Label ExpansionThe FDA's approval of the CLEAR label expansion represents a seminal moment for the company.
Market PotentialThe new FDA label expands the TAM from 10M to 70M and a vast majority of this stems from primary prevention, creating a large and untapped opportunity for an oral treatment.
Bears Say
Financial HealthMaximizing the impact of this positive label may take some significant marketing muscle at a time when Esperion is cash-strapped.
Market CompetitionCapturing meaningful share may not be straightforward in the primary prevention market due to underutilization of generic and more effective statins.
Stock ValuationThe analyst has lowered the price target to $8 from $10, primarily reflecting recent equity dilution.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
7.95% Other Institutional Investors
92.05% Public Companies and
Individual Investors
0ET FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was €0.67 and its highest was €2.99 in the past 12 months.
What is Esperion’s market cap?
Currently, no data Available
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is May 07, 2024 which is in 3 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Feb 27, 2024. The company reported -€0.467 earnings per share for the quarter, missing the consensus estimate of -€0.45 by -€0.017.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is €0.05.
How many shares outstanding does Esperion have?
Currently, no data Available
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -€0.467 in its last earnings report, missing expectations of -€0.45. Following the earnings report the stock price went up 0.207%.
Which hedge fund is a major shareholder of Esperion?
Among the largest hedge funds holding Esperion’s share is Platinum Investment Management. It holds Esperion’s shares valued at 8M.
---
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.90 (263.03% Upside)
€6.90 (263.03% Upside)
Blogger Sentiment
Bullish
DE:0ET Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.00%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
0ET Company Deck
---
0ET Earnings Call
Q4 2024
0:00 / 0:00
---
0ET Stock 12 Months Forecast
Average Price Target
€6.90
▲(263.03% Upside)
Technical Analysis
Best Analysts Covering 0ET
1 Year
1 Year Success Rate
9/26 ratings generated profit
1 Year Average Return
+26.93%
reiterated a buy rating last month
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 34.62% of your transactions generating a profit, with an average return of +26.93% per trade.
---